Teva Pharmaceutical Industries Limited (TEVA)
Market Cap | 18.62B |
Revenue (ttm) | 16.00B |
Net Income (ttm) | -493.00M |
Shares Out | 1.12B |
EPS (ttm) | -0.44 |
PE Ratio | n/a |
Forward PE | 5.59 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 2,316,030 |
Open | 16.70 |
Previous Close | 16.81 |
Day's Range | 16.58 - 16.80 |
52-Week Range | 7.09 - 17.13 |
Beta | 1.05 |
Analysts | Buy |
Price Target | 14.22 (-14.44%) |
Earnings Date | May 8, 2024 |
About TEVA
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. ... [Read more]
Full Company ProfileFinancial Performance
In 2023, TEVA's revenue was $15.85 billion, an increase of 6.17% compared to the previous year's $14.93 billion. Losses were -$559.00 million, -77.15% less than in 2022.
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for TEVA stock is "Buy." The 12-month stock price forecast is $14.22, which is a decrease of -14.44% from the latest price.
News
Teva Announces Appointment of Matthew Shields to Executive Vice President, Teva Global Operations
TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the appointment of Matthew Shields as Executive Vice President of Teva Global Operations (T...
Teva Pharmaceutical's stock climbs as schizophrenia treatment shows promise
Teva Pharmaceutical Industries Ltd.'s American depositary receipts TEVA jumped more than 6% premarket Wednesday after the company reported first-quarter sales that topped expectations and released pos...
Teva Pharm Q1 profit falls short of estimates, revenue gains
Teva Pharmaceutical Industries reported a smaller than expected rise in first-quarter profit citing higher impairments of tangible assets, while sales of copycat medicines and its branded drugs to tre...
Teva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial Outlook
TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the quarter ended March 31, 2024. Mr. Richard Francis, Teva's President and CEO,...
Teva and Medincell's schizophrenia drug meets main goal of late-stage study
Teva Pharmaceuticals , and partner Medincell said on Wednesday their experimental schizophrenia drug had met its main goal in a late-stage study.
Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia
PARSIPPANY, N.J. & TEL AVIV, Israel & PARIS--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Medincell (Euronext: MEDCL), toda...
Teva Earnings Are Coming. What Could Keep the Stock Gains Going.
The pharmaceutical company reports before the market open Wednesday.
Teva to Present at the 2024 Bank of America Healthcare Conference
TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the 2024 Bank of America He...
Teva's 2023 Healthy Future Report Showcases Renewed Sustainability Strategy and Ambitious Targets
TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today published its 2023 Healthy Future Report, sharing its actions to promote healthy people, a healthy pl...
FTC Warns ‘Junk Patents' Could Make Drugs Like Ozempic Pricier—Here's How
The Federal Trade Commission is challenging hundreds of alleged “junk” patent listings filed by several pharmaceutical companies, which regulators claim could increase prices for medications like Novo...
Teva's New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO® (deutetrabenazine) Tablets
TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced final results from the HD coh...
Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China
TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced results from a Phase 3 study ...
Teva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, 2024
TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its first quarter 2024 financial results on Wednesday...
New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension at SIRS 2024
TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the presentation of eight stu...
Teva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar Candidate
TEL AVIV, Israel, & MADRID--(BUSINESS WIRE)--Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and mAbxience, a Fresenius Kabi majority...
Teva, Viatris win new chance to challenge J&J schizophrenia drug patent
Teva Pharmaceutical and Viatris convinced a U.S. appeals court on Monday to revive their challenges to a patent covering a blockbuster Johnson & Johnson schizophrenia drug, giving them a new chance to...
Teva UK and Closed Loop Medicine Announce Strategic Partnership to Advance Development of Personalised Medicines
CASTLEFORD, England & LONDON--(BUSINESS WIRE)--Teva UK Limited and Closed Loop Medicine Ltd have announced a strategic partnership to advance the development of personalised medicines. Under the agree...
Teva and Jiangsu Nhwa Forge Strategic Partnership to Promote Patient Access to AUSTEDO® in China
SHANGHAI & TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Investments Singapore Pte Ltd (TPIS), a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Jiangsu Nhwa Pharm...
Teva Presents New Data Supporting Safety, Tolerability and Target Engagement of Anti-TL1A (TEV-‘574) Antibody at the 2024 ECCO Annual Meeting
TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced positive safety, tolerability...
Teva Pharm to stay as unified generics, branded drugmaker, CEO says
Teva Pharmaceutical Industries will remain a single company for both generic and branded drugs since generics help to fund research and development of its innovative medicines, Chief Executive Richard...
Teva Canada Named by Forbes as No. 1 Canadian Employer in Drugs & Biotechnology Industry
TORONTO--(BUSINESS WIRE)--Teva Canada Named by Forbes as No. 1 Canadian Employer in Drugs & Biotechnology Industry.
Teva's CEO talks Q4 earnings and how he is implementing his 'pivot to growth' strategy
Shares of Teva Pharmaceuticals (TEVA) are trending up as the company reported its fourth-quarter earnings, beating Wall Street expectations on both its top and bottom line. On Wednesday, the company c...
MedinCell's Partner Teva Provides Guidance for UZEDY in 2024 and an Update on the Treatment-Candidate of Olanzapine Long-Acting Injectable (LAI)
MONTPELLIER, France--(BUSINESS WIRE)--MedinCell (Paris:MEDCL): Access here the complete press release About UZEDY During the Q4 2023 earnings call held today by Teva Pharmaceutical Industries Ltd., Pr...
Teva Pharma CEO Richard Francis on Q4 earnings
Richard Francis, Teva Pharmaceuticals CEO, joins 'Money Movers' to discuss the company's recent divestiture, how easy it'll be to disentangle from part of its business, and more.
Teva Reports Growth in Fourth Quarter and Full Year 2023
TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the year and the quarter ended December 31, 2023. Q4 2023 and Full Year 2023 Hig...